Citadel Advisors’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-140,474
| Closed | -$3.94M | – | 14862 |
|
|
2022
Q1 | $3.94M | Buy |
140,474
+114,347
| +438% | +$3.13M | ﹤0.01% | 4643 |
|
|
2021
Q4 | $714K | Sell |
26,127
-87,157
| -77% | -$2.36M | ﹤0.01% | 8786 |
|
|
2021
Q3 | $3.08M | Sell |
113,284
-383,986
| -77% | -$9.5M | ﹤0.01% | 5293 |
|
|
2021
Q2 | $8.5M | Sell |
497,270
-216,287
| -30% | -$4.05M | ﹤0.01% | 3363 |
|
|
2021
Q1 | $14.9M | Sell |
713,557
-272,382
| -28% | -$6.29M | ﹤0.01% | 2375 |
|
|
2020
Q4 | $22.6M | Sell |
985,939
-162,235
| -14% | -$3.09M | 0.01% | 1674 |
|
|
2020
Q3 | $18.7M | Buy |
1,148,174
+1,036,612
| +929% | +$18.8M | 0.01% | 1638 |
|
|
2020
Q2 | $1.51M | Buy |
111,562
+73,739
| +195% | +$858K | ﹤0.01% | 5060 |
|
|
2020
Q1 | $449K | Buy |
37,823
+1,776
| +5% | +$39.4K | ﹤0.01% | 6634 |
|
|
2019
Q4 | $898K | Sell |
36,047
-186,492
| -84% | -$3.78M | ﹤0.01% | 5797 |
|
|
2019
Q3 | $3.79M | Sell |
222,539
-54,144
| -20% | -$986K | ﹤0.01% | 3505 |
|
|
2019
Q2 | $6.3M | Buy |
276,683
+251,273
| +989% | +$6.78M | ﹤0.01% | 2765 |
|
|
2019
Q1 | $816K | Sell |
25,410
-30,105
| -54% | -$932K | ﹤0.01% | 5962 |
|
|
2018
Q4 | $1.56M | Sell |
55,515
-100,215
| -64% | -$2.94M | ﹤0.01% | 4555 |
|
|
2018
Q3 | $4.48M | Buy |
155,730
+138,334
| +795% | +$4.16M | ﹤0.01% | 3148 |
|
|
2018
Q2 | $651K | Sell |
17,396
-16,718
| -49% | -$656K | ﹤0.01% | 5940 |
|
|
2018
Q1 | $1.34M | Sell |
34,114
-69,660
| -67% | -$2.54M | ﹤0.01% | 4355 |
|
|
2017
Q4 | $3.36M | Buy |
103,774
+65,017
| +168% | +$1.95M | ﹤0.01% | 2963 |
|
|
2017
Q3 | $1.21M | Sell |
38,757
-26,347
| -40% | -$780K | ﹤0.01% | 4047 |
|
|
2017
Q2 | $1.82M | Buy |
65,104
+54,297
| +502% | +$1.23M | ﹤0.01% | 3299 |
|
|
2017
Q1 | $185K | Sell |
10,807
-35,389
| -77% | -$496K | ﹤0.01% | 6580 |
|
|
2016
Q4 | $559K | Sell |
46,196
-285,756
| -86% | -$3.7M | ﹤0.01% | 4729 |
|
|
2016
Q3 | $5.26M | Buy |
331,952
+263,768
| +387% | +$3.97M | 0.01% | 1927 |
|
|
2016
Q2 | $882K | Buy |
68,184
+49,787
| +271% | +$779K | ﹤0.01% | 3718 |
|
|
2016
Q1 | $350K | Buy |
+18,397
| New | +$333K | ﹤0.01% | 4896 |
|
|
2015
Q3 | – | Sell |
-21,054
| Closed | -$602K | – | 9360 |
|
|
2015
Q2 | $602K | Buy |
+21,054
| New | +$552K | ﹤0.01% | 4688 |
|
|
2014
Q4 | – | Sell |
-10,894
| Closed | -$169K | – | 8823 |
|
|
2014
Q3 | $169K | Buy |
+10,894
| New | +$164K | ﹤0.01% | 5904 |
|
Citadel Advisors's XENT Position: Q2 2022 in Review
Citadel Advisors sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 140,474 shares — an estimated $3.94M sold.
Citadel Advisors first reported a position in XENT in Q3 2014 and held it in 27 quarters. The position peaked at $22.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Citadel Advisors reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 140,474 Intersect ENT, Inc shares in Q2 2022, an estimated $3.94M.
- Citadel Advisors first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 27 quarters.
- Citadel Advisors's Intersect ENT, Inc position peaked at $22.6M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.